2. Search Result
Search Result
Results for "

Ag

" in MedChemExpress (MCE) Product Catalog:

227

Inhibitors & Agonists

1

Screening Libraries

8

Fluorescent Dyes

1

Biochemical Assay Reagents

6

Peptides

3

MCE Kits

3

Inhibitory Antibodies

5

Natural
Products

41

Recombinant Proteins

15

Isotope-Labeled Compounds

26

Antibodies

2

Click Chemistry

7

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-104042
    Vorasidenib
    5+ Cited Publications

    Ag-881

    		 Isocitrate Dehydrogenase (IDH) Cancer
    Vorasidenib (AG-881) is an orally available, brain penetrant second-generation dual mutant isocitrate dehydrogenases 1 and 2 (mIDH1/2) inhibitor. Vorasidenib (AG-881) exhibits nanomolar inhibition of (D)-2-hydroxyglutarate (D-2-HG), and the IC50 ranges of 0.04~22 nM against IDH1 R132C, IDH1 R132G, IDH1 R132H and IDH1 R132S and 7~14 nM against IDH2 R140Q and 130 nM against IDH2 R172K. Vorasidenib can be used for the study of grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1/2 mutation .
    Vorasidenib
  • HY-13524
    AG-1478
    45+ Cited Publications

    Tyrphostin Ag-1478; NSC 693255

    		 EGFR HCV Influenza Virus Infection Cardiovascular Disease Metabolic Disease Cancer
    AG-1478 (Tyrphostin AG-1478) is a selective EGFR tyrosine kinase inhibitor with IC50 of 3 nM. AG-1478 has antiviral effects against HCV and encephalomyocarditis virus (EMCV).
    AG-1478
  • HY-12000
    AG490
    Maximum Cited Publications
    165 Publications Verification

    Tyrphostin Ag490; Tyrphostin B42

    		 EGFR STAT JAK Autophagy Cancer
    AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3.
    AG490
  • HY-18767
    Ivosidenib
    15+ Cited Publications

    Ag-120

    		 Isocitrate Dehydrogenase (IDH) Metabolic Disease Cancer
    Ivosidenib (AG-120) is an orally active inhibitor of isocitrate dehydrogenase 1 mutant (mIDH1) enzyme, it exhibits profound d-2-hydroxyglutatrate (2-HG) lowering in vivo. Ivosidenib (AG-120) has the potential for AML therapy due to its acceptable safety profile and clinical activity .
    Ivosidenib
  • HY-15287
    Nelfinavir
    15+ Cited Publications

    Ag1341

    		 HIV Protease HIV Infection Cancer
    Nelfinavir (AG-1341) is a potent and orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) for HIV infection. Nelfinavir is a broad-spectrum, anticancer agent .
    Nelfinavir
  • HY-13662
    Lansoprazole
    3 Publications Verification

    Ag-1749

    		 Exosomes Proton Pump Bacterial Phospholipase Inflammation/Immunology Cancer
    Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .
    Lansoprazole
  • HY-138630
    AG-270
    5+ Cited Publications

    		 Methionine Adenosyltransferase (MAT) Cancer
    AG-270 is an allosteric, noncompetitive, first-in-class, reversible and orally active MAT2A inhibitor, with an IC50 of 14 nM .
    AG-270
  • HY-12689
    Mitapivat
    3 Publications Verification

    Ag-348

    		 Pyruvate Kinase Metabolic Disease
    Mitapivat (AG-348) is an orally active pyruvate kinase allosteric activator. Mitapivat increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes, shows the potential to restore the activity of PK (pyruvate kinase)-deficient glycolytic pathways. Mitapivat can be used in study of PK deficiency .
    Mitapivat
  • HY-11062
    Icilin
    1 Publications Verification

    Ag-3-5

    		 TRP Channel Neurological Disease Inflammation/Immunology
    Icilin (AG-3-5) is a super-agonist of the transient receptor potential M8 (TRPM8) ion channel. Icilin activates TRPM8 in EGTA in a dose-dependent manner (EC50=1.4 μM). Icilin is a "super-cooling agent" . Icilin attenuates autoimmune neuroinflammation through modulation of the T-cell response .
    Icilin
  • HY-15287A
    Nelfinavir Mesylate
    15+ Cited Publications

    Ag 1343 Mesylate

    		 HIV Protease HIV Infection Cancer
    Nelfinavir Mesylate (AG 1343 Mesylate) is a potent and orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) for HIV infection. Nelfinavir Mesylate (AG 1343 Mesylate) is a broad-spectrum, anticancer agent .
    Nelfinavir Mesylate
  • HY-10253
    AG1024
    5+ Cited Publications

    Tyrphostin Ag 1024

    		 IGF-1R Insulin Receptor Apoptosis Endocrinology Cancer
    AG1024 (Tyrphostin AG 1024) is a reversible, competitive and selective IGF-1R inhibitor with an IC50 of 7 μM. AG1024 inhibits phosphorylation of IR (IC50=57 μM). AG1024 induces apoptosis and has anti-cancer activity .
    AG1024
  • HY-101957
    AG 1295
    4 Publications Verification

    		 PDGFR Cardiovascular Disease
    AG 1295 is a selective platelet-derived growth factor receptor (PDGFR) tyrosine-kinase inhibitor. AG1295 abolishes autophosphorylation of the PDGFR whereas not affects the autophosphorylation of the EGF receptor .
    AG 1295
  • HY-10534
    Voreloxin
    3 Publications Verification

    SNS-595; Vosaroxin; Ag 7352

    		 Topoisomerase Apoptosis Cancer
    Voreloxin (SNS-595; Vosaroxin; AG 7352) is a first-in-class topoisomerase II inhibitor that intercalates DNA and induces site-selective DNA DSB, G2 arrest, and apoptosis.
    Voreloxin
  • HY-12032
    AG14361
    5+ Cited Publications

    		 PARP Cancer
    AG14361 is a potent PARP-1 inhibitor, with a Ki of < 5 nM, and in permeabilized SW620 and intact SW620 cells, the IC50s are 29 nM and 14 nM, respectively.
    AG14361
  • HY-108474
    Nolatrexed dihydrochloride
    2 Publications Verification

    Ag 337

    		 Thymidylate Synthase Cancer
    Nolatrexed dihydrochloride (AG 337) is an orally active and non-competitive lipophilic inhibitor of thymidylate synthase with a Ki of 11 nM for human thymidylate synthase. Nolatrexed dihydrochloride interacts at the folate cofactor binding site of the enzyme. Nolatrexed dihydrochloride increases sulfotransferases. Nolatrexed dihydrochloride induces cell cycle arrest in S phase of cancer cells. Nolatrexed dihydrochloride exhibits anticancer activity against cervical cancer.
    Nolatrexed dihydrochloride
  • HY-15491
    AG-024322

    		COX Apoptosis Cancer
    AG-024322 is a potent ATP-competitive pan-CDK inhibitor against cell cycle kinases CDK1, CDK2, and CDK4 with Ki values in the 1-3 nM range . AG-024322 displays broad-spectrum anti-tumor activity and clear target modulation in vivo. AG-024322 induces cell apoptosis .
    AG-024322
  • HY-108330
    AG126
    3 Publications Verification

    Tyrphostin Ag126

    		 ERK Mitosis Inflammation/Immunology
    AG126 is a tyrosine kinase inhibitor, can inhibit the phosphorylation of ERK1 and ERK2 at 25-50 μM. AG126 can be used in meiosis, mitosis, and postmitotic research .
    AG126
  • HY-13894
    Tyrphostin AG1296
    3 Publications Verification

    Ag1296

    		 PDGFR c-Kit FLT3 Apoptosis Cardiovascular Disease Inflammation/Immunology Cancer
    Tyrphostin AG1296 is a potent and selective inhibitor of platelet-derived growth factor receptor (PDGFR), with an IC50 of 0.8 μM. Tyrphostin AG1296 inhibits signaling of human PDGF α- and β-receptors as well as of the related stem cell factor receptor (c-Kit). Tyrphostin AG1296 is also a potent inhibitor of FLT3, with an IC50 in the micromolar range .
    Tyrphostin AG1296
  • HY-109165A
    Acoramidis hydrochloride

    Ag10 hydrochloride

    		 Transthyretin (TTR) Metabolic Disease Endocrinology
    Acoramidis (AG10) hydrochloride is an orally active and selective kinetic stabilizer of WT and V122I-TTR (transthyretin). Acoramidis (AG10) hydrochloride is used in the study for transthyretin amyloidosis .
    Acoramidis hydrochloride
  • HY-109165
    Acoramidis

    Ag10

    		 Transthyretin (TTR) Metabolic Disease Endocrinology
    Acoramidis (AG10) is an orally active and selective kinetic stabilizer of WT and V122I-TTR (transthyretin). Acoramidis (AG10) is used in the study for transthyretin amyloidosis .
    Acoramidis
  • HY-14530
    Pelitrexol
    2 Publications Verification

    Ag 2037

    		 Antifolate Cancer
    Pelitrexol (AG 2037) is an inhibitor of glycinamide ribonucleotide formyltransferase (GARFT), a purine biosynthetic enzyme. Pelitrexol also inhibits mTORC1 by reducing GTP-bound Rheb level, a mTORC1 obligate activator. Pelitrexol shows robust tumor growth suppression in mice .
    Pelitrexol
  • HY-172435
    Rezuforimod

    AgN-232411; Ag-80308; AgN-411

    		 Formyl Peptide Receptor (FPR) Neurological Disease
    Rezuforimod (AGN-232411; AG-80308) is an ophthalmic solution targeting the formyl peptide receptor (FPR) pathway. Rezuforimod exerts anti-inflammatory effects by targeting the formyl peptide receptor pathway. Administered topically, Rezuforimod significantly reduces the corneal conjunctival staining score and improves ocular discomfort symptoms, with no serious adverse events reported and favorable overall safety profile. Rezuforimod shows remarkable potential to serve as a novel therapeutic option for dry eye disease .
    Rezuforimod
  • HY-14346
    PD153035
    5+ Cited Publications

    SU-5271; Ag1517; ZM 252868

    		 EGFR Cancer
    PD153035 (SU-5271; AG1517; ZM 252868) is a potent EGFR inhibitor with Ki and IC50 of 6 and 25 pM, respectively.
    PD153035
  • HY-115625
    AG-205

    		Progesterone Receptor Apoptosis Glycosyltransferase Cancer
    AG-205 is a progesterone receptor membrane component 1 (PGRMC1) antagonist and CGT inhibitor, with an IC50 of 50 μM against rat CGT. AG-205 exhibits antimitotic, antimigratory and anti-invasive activities. AG-205 increases the expression of genes encoding cholesterol biosynthesis pathway or steroidogenic enzymes. AG-205 promotes the regulation of cell cycle by apoptosis and reduces the migratory and invasive capacities of ovarian and breast cancer cells. AG-205 can be used in research related to renal cancer and breast cancer .
    AG-205
  • HY-19326
    SU1498
    5+ Cited Publications

    Ag 1498; Tyrphostin SU 1498

    		 VEGFR Inflammation/Immunology Cancer
    SU1498 (AG 1498) is a selective inhibitor of the VEGFR2; inhibits Flk-1 with an IC50 of value of 700 nM .
    SU1498
  • HY-101042
    AG-494

    Tyrphostin Ag 494

    		 EGFR CDK Cancer
    AG-494 (Tyrphostin AG 494) is a potent and selective EGFR tyrosine kinase inhibitor (IC50=0.7 μM). AG-494 inhibits the autophosphorylation of EGFR, ErbB2, HER1-2 and PDGF-R with IC50s 1.1, 39, 45 and 6 μM, respectively. AG-494 blocks Cdk2 activation and inhibits EGF-dependent DNA synthesis .
    AG-494
  • HY-20878
    Tyrphostin AG 879
    3 Publications Verification

    Ag 879

    		 Trk Receptor EGFR Apoptosis Cancer
    Tyrphostin AG 879 (AG 879) is a tyrosine kinase inhibitor that inhibits TrKA phosphorylation (IC50 of 10 μM), but not TrKB and TrKC. Tyrphostin AG 879 is also a selective ErbB2 tyrosine kinase inhibitor with an IC50 of 1 μM, and has at least 500-fold higher selectivity to ErbB2 than EGFR. Tyrphostin AG 879 has anticancer activity .
    Tyrphostin AG 879
  • HY-15336
    AG 555

    Tyrphostin Ag 555

    		 EGFR Reverse Transcriptase Cancer
    AG 555 (Tyrphostin AG 555), a potent antiretroviral agent, is a potent and selective inhibitor of EGFR and blocks Cdk2 activation .
    AG 555
  • HY-137463
    AG-636
    2 Publications Verification

    		 Dihydroorotate Dehydrogenase DNA/RNA Synthesis Cancer
    AG-636 is a potent, reversible, selective and orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 17 nM. AG-636 has strong anticancer effects .
    AG-636
  • HY-19476
    AG-7404

    		Virus Protease Infection
    AG-7404 is an orally active, irreversible inhibitor of the picornavirus 3C protease. AG-7404 blocks the processing of viral polyproteins, thereby inhibiting viral replication. AG-7404 has synergistic antiviral activity with capsid inhibitors such as V-073 (HY-104074) or BTA798 (HY-106254) and is effective against V-073-resistant variants. AG-7404 is used in the study of enterovirus infections such as poliovirus .
    AG-7404
  • HY-10065S1
    Axitinib-d3

    Ag-013736-d3

    		 VEGFR Cancer
    Axitinib-d3 (AG-013736-d3) is deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively .
    Axitinib-d3
  • HY-101961
    Tyrphostin AG 1288

    Ag 1288

    		 c-Kit Inflammation/Immunology
    Tyrphostin AG 1288 is a potent Tyrosine Kinase inhibitor. Tyrphostin AG 1288 inhibits ICAM1 expression and TNFα-mediated cytotoxicity in vitro .
    Tyrphostin AG 1288
  • HY-119715
    AG-012986

    		CDK Apoptosis Inflammation/Immunology Cancer
    AG-012986 is a pan-CDK inhibitor with Ki values of 44 nM (CDK1), 9.2 nM (CDK4), 94 nM (CDK2), and IC50 values of 22 nM (CDK5), 4 nM (CDK9). AG-012986 causes apoptosis of T-cells by targeting upstream kinases in the p38 Mitogen-activated protein kinase (MAPK) pathway and impairing cellular survival. AG-012986 induces cell cycle arrest, retinoblastoma protein hypophosphorylation, and reduces Ki-67 expression. AG-012986 exerts antiproliferative activity in tumor cells, demonstrates antitumor efficacy in human xenograft models, and causes retinal and peripheral neurotoxicity, plus immune cell toxicity. AG-012986 can be used for the research of colon carcinoma, non-small cell lung carcinoma, lung carcinoma, breast carcinoma, ovarian tumor, pancreatic carcinoma, osteosarcoma, lymphoma, leukemia, retinotoxicity .
    AG-012986
  • HY-128113
    AG-09/1

    		Formyl Peptide Receptor (FPR) Inflammation/Immunology
    AG-09/1 is a specific formyl peptide receptor 1 (FPR1) agonist. N-formyl peptide receptors (FPR) are important in host defense .
    AG-09/1
  • HY-118283
    5-Hydroxylansoprazole
    1 Publications Verification

    Ag1908

    		 Proton Pump Metabolic Disease
    5-Hydroxylansoprazole (AG1908) is an active metabolite of Lansoprazole in plasma. Lansoprazole is metabolized by CYP2C19 forming 5-Hydroxylansoprazole. Lansoprazole is a gastric proton-pump inhibitor and is effective in the treatment of various peptic diseases .
    5-Hydroxylansoprazole
  • HY-118532
    Tyrphostin AG30
    1 Publications Verification

    Ag30

    		 EGFR Cancer
    Tyrphostin AG30 (AG30) is a potent and selective EGFR tyrosine kinase inhibitor. Tyrphostin AG30 (AG30) selectively inhibits self renewal induction by c-ErbB, and is able to inhibit activation of STAT5 by c-ErbB in primary erythroblasts .
    Tyrphostin AG30
  • HY-117718
    AG957

    Tyrphostin Ag957; NSC 654705

    		 Bcr-Abl Cancer
    AG957 (Tyrphostin AG957;NSC 654705) is a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity . AG957 is a bcr/abl kinase inhibitor with an IC50 of 2.9 μM for p210 bcr/abl autokinase activity .
    AG957
  • HY-100499
    Tyrphostin AG 528
    1 Publications Verification

    Tyrphostin B66; Ag 528

    		 EGFR Cancer
    Tyrphostin AG 528 is an inhibitor of EGFR and ErbB2 with IC50s of 4.9 and 2.1 μM, respectively. Tyrphostin AG 528 (Tyrphostin B66) is a protein tyrosine kinase inhibitor, with IC50s of 4.9 μM for epidermal growth factor receptors (EGFR) and 2.1 μM for ErbB2 . Tyrphostin AG 528 is also an anticancer agent .
    Tyrphostin AG 528
  • HY-119757
    Tyrphostin AG1433

    SU1433; Ag1433

    		 PDGFR VEGFR Cancer
    Tyrphostin AG1433 (SU1433) is a tyrosine kinases inhibitor. AG1433 is also a selective PDGFRβ and VEGFR-2 (Flk-1/KDR) inhibitor with IC50s of 5.0 μM and 9.3 μM, respectively. Tyrphostin AG1433 prevents blood vessel formation .
    Tyrphostin AG1433
  • HY-135436
    AG 538

    		IGF-1R Cancer
    AG 538 is a potent, competitive inhibitor of IGF-1 receptor kinase, with an IC50 of 400 nM .
    AG 538
  • HY-W008614
    Lansoprazole sulfone
    1 Publications Verification

    Ag-1813

    		 Drug Metabolite Proton Pump Metabolic Disease
    Lansoprazole sulfone (AG-1813) is an orally active and selective inhibitor of H +, K +-ATPase. Lansoprazole sulfone can significantly stimulates gastric acid secretion by inhibiting H +, K +-ATPase. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .
    Lansoprazole sulfone
  • HY-12806
    AG1557

    		EGFR Cancer
    AG1557 is a specific and ATP competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, has a pIC50 value of 8.194 .
    AG1557
  • HY-16668
    Tyrphostin A1
    1 Publications Verification

    Tyrphostin 1; Ag9

    		 Interleukin Related Inflammation/Immunology
    Tyrphostin A1(AG9) inhibits CD40L-stimulated IL-12 production in macrophage cultures and antigen-induced generation of Th1 cells.
    Tyrphostin A1
  • HY-15492
    AG-13958
    1 Publications Verification

    Ag-013958

    		 VEGFR Cardiovascular Disease
    AG-13958 (AG-013958), a potent VEGFR tyrosine kinase inhibitor, is used for treatment of choroidal neovascularization associated with age-related macular degeneration (AMD) .
    AG-13958
  • HY-118143
    AG-1801

    		Endogenous Metabolite Others
    AG-1801, a nitrobenzopyridine derivative, is a tyrosine phosphorylation inhibitor. AG-1801 can induce the disintegration of the microtubule network in living cells, and does not inhibit microtubule polymerization in vitro. AG-1801 can be used for the study of microtubule-related signaling pathways .
    AG-1801
  • HY-15844
    AG-825
    1 Publications Verification

    Tyrphostin Ag-825

    		 EGFR Apoptosis Adrenergic Receptor Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    AG-825 is a selective, ATP-competitive, tyrosine phosphorylation ErbB2 inhibitor with an IC50 of 0.35 μM. AG825 significantly accelerates Apoptosis of human neutrophils. AG-825 increases β1AR density. AAG-825 has anticancer and anti-inflammatory activities. AAG-825 can be used in cardiovascular disease research .
    AG-825
  • HY-P991664
    AG01

    		Src Akt ERK TAM Receptor c-Met/HGFR MMP HIF/HIF Prolyl-Hydroxylase VEGFR Cancer
    AG01 is a monoclonal antibody against progranulin (GP88). AG01 inhibits triple-negative breast cancer (TNBC) cell proliferation and migration, reduces the expression of phosphorylated protein kinases p-Src, p-AKT, and p-ERK, and reduces the expression of oncogenic proteins such as Axl, c-MET, HIF-1α, and VEGF. AG01 inhibits tumor growth and Ki67 expression in a TNBC xenograft mouse model. AG01 can be used in the research of TNBC and other cancers .
    AG01
  • HY-108931
    AG 1406

    		EGFR Cancer
    AG 1406 (compound M19) is a HER2 inhibitor, with an IC50 of 10.57 μM for HER2 in BT474 cell and >50 μM for EGFR in EGF-3T3 cell .
    AG 1406
  • HY-15287R
    Nelfinavir (Standard)

    Ag1341 (Standard)

    		 Reference Standards HIV Protease HIV Infection Cancer
    Nelfinavir (Standard) is the analytical standard of Nelfinavir. This product is intended for research and analytical applications. Nelfinavir (AG-1341) is a potent and orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) for HIV infection. Nelfinavir is a broad-spectrum, anticancer agent .
    Nelfinavir (Standard)
  • HY-13714
    Nolatrexed

    Ag 337 free base

    		 Antifolate Others
    Nolatrexed (AG 337 free base) is a compound with antifolate activity, high oral bioavailability, and major toxicity at inhibitory doses is gastrointestinal reactions. It can be safely taken orally at specific doses for inhibition, with effects on platelets and neutrophils.
    Nolatrexed

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: